The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 5 December 2005. doi:10.1084/jem20211iti1
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 202, Number 11, 1456-1456
This Article
Right arrow Full Text (PDF, 654K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Epps, H. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Van Epps, H. L.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

IN THIS ISSUE

NPY's mixed messages


Neuropeptide Y (NPY) stimulates cytokine production from antigen-presenting cells, but inhibits it from T cells.

A stress hormone sends mixed signals to immune cells, according to a study on page 1527. Wheway and colleagues show that neuropeptide Y (NPY) activates antigen-presenting cells (APCs) but shuts off T cells. If correctly sequenced, these activities would both turn on and then limit certain immune responses.NPY is an abundant neuropeptide that is released from sympathetic nerve endings. In the brain, NPY regulates physiological and emotional processes, including metabolism, heart rate, and depression. NPY is also produced by activated immune cells and has been shown to dampen cytokine production by macrophages and inhibit the killer activity of natural killer cells.

The effects of NPY on T cells, however, have been controversial. Treatment with NPY ameliorates autoimmune disease in a mouse model of multiple sclerosis, suggesting a suppressive effect on the disease-inducing T helper (Th)-1 cells. But mice lacking the major lymphoid receptor for NPY (Y1) were protected from colitis, another Th1-driven autoimmune disease, suggesting that NPY signaling normally activates Th1 cells.

The study by Wheway and colleagues helps clear up these conflicting reports. They show that NPY indeed inhibits Th1 responses, as T cells from Y1-deficient mice produced more interferon (IFN)-{gamma} than wild-type cells when stimulated in vitro. When transferred, Y1-deficient T cells were hyperactive and triggered more severe colitis in recipient mice than did wild-type T cells.

However, the receptor-deficient mice themselves were resistant to T cell–mediated colitis when treated with an intestinal irritant. The defect was traced to APCs, which could not be activated in the absence of NPY signaling. APCs from the Y1-deficient mice failed to produce the Th1-promoting cytokines interleukin-12 and TNF and could not activate naive T cells. These mice were thus protected because the T cell response never got started.

How is a T cell response ever mounted if the same signal that turns on the APC turns off the T cell? The authors suspect that it comes down to timing. The expression of the Y1 receptor on T cells might be induced only after activation, thus providing a negative feedback loop that keeps activated T cells from running amok. The authors now plan to study NPY-induced signaling in different cell types to determine how the same molecule tells some cells to go and others to stop. {JEMiti_end}



Heather L. Van Epps

hvanepps{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

A fundamental bimodal role for neuropeptide Y1 receptor in the immune system
Julie Wheway, Charles R. Mackay, Rebecca A. Newton, Amanda Sainsbury, Dana Boey, Herbert Herzog, and Fabienne Mackay
J. Exp. Med. 2005 202: 1527-1538. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF, 654K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Epps, H. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Van Epps, H. L.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS